Clinical trials advancing proton therapy research open at the CDH Proton Center, A ProCure Center

Five clinical trials evaluating proton therapy as a treatment for cancer, including one involving children with brain cancer and three trials for men with prostate cancer, are being led by researchers at CDH Proton Center, A ProCure Center.

“We recently returned from a national medical meeting where more than 70 papers and posters were presented assessing the use of proton therapy in treating cancer, and the results continue to be impressive,” said Dr. William Hartsell, the Center’s medical director. “Our clinical trials are part of a national effort to assess new and what we anticipate will be better ways to treat patients with proton therapy.”
The pediatric trial is evaluating the simultaneous use of chemotherapy regimens and radiation therapy, which includes proton radiation as an option. The trial (code: NCT00867178) involves infants born with tumors of the central nervous system, such as medulloblastoma, and will assess proton beam as an acceptable form of radiation.
One of the prostate cancer trials (code: NCT01230866) is treating patients using higher doses of proton therapy treatment over a much shorter time period (five treatments over one to two weeks) than current standards (44 treatments over as many as nine weeks). A second prostate cancer trial looks at the impact of combining hormone (androgen deprivation) therapy with proton therapy (code: NCT01492972).

“We hope to learn more about the effectiveness and potential benefits of treating patients with proton therapy in new ways or combined with other important treatments,” Hartsell said.
Proton therapy is an advanced form of radiation treatment for many cancerous and non-cancerous tumors, including tumors of the brain, central nervous system, head and neck, lung and prostate, as well as sarcomas and many pediatric cancers. The precision of proton therapy makes it especially effective for treating children and adults with anatomically complex tumors such as base of skull and tumors along the spinal cord.

To learn more about proton therapy and the CDH Proton Center, A ProCure Center, go to http://www.procure.com/il.

To learn more about the five clinical trials, go to http://www.clinicaltrials.gov and search for the following identifier codes:
•       NCT01230866 (“Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer”)
•       NCT01492972 (“Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer”)
•       NCT00867178 (“Vorinostat, Isotretinoin, and Combination Chemotherapy in Treating Young Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System”)
•       NCT01255748 (“Registry Study for Proton Therapy Outcomes”)
•       NCT01603420 (“External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer”)

In addition to these trials, the Center is also working with collaborating institutions on several studies that allow for the use of proton therapy, including:
•       NCT00085735 (“A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial”)
•       NCT00392327 (“Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients”)
•       NCT00653068 (“Treatment of Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation”) •       NCT01602666 (“Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors”) •       NCT01182350 (“Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas”)
•       NCT01222754 (“A Phase I Trial of Lenalidomide and Radiotherapy in children with Diffuse Intrinsic Pontine Gliomas and High-Grade Gliomas“)
•       NCT01088035 (“Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma”)

About CDH Proton Center, A ProCure Center: CDH Proton Center, A ProCure Center, Warrenville, Ill., is one of a handful of facilities in the country that offer proton therapy, an advanced form of radiation to treat cancer. The four-room, 60,000 sq. ft. Center, opened Oct. 19, 2010, is the first for Illinois and has the capacity to treat up to 1,500 patients a year. The precision of proton therapy spares healthy tissue and results in fewer short- and long-term side effects than treatment with standard X-ray radiation therapy. Proton therapy has been shown to be beneficial in the treatment of a broad range of tumor types including head and neck, brain, central nervous system, prostate, lung, sarcomas, gastrointestinal and many pediatric cancers. It is especially effective for treating children and adults with anatomically complex tumors such as at the base of the skull and tumors along the spinal cord. The CDH Proton Center, A ProCure Center, is a collaboration between Central DuPage Hospital (CDH), Radiation Oncology C! onsultants (ROC) and ProCure Treatment Centers, Inc. ProCure was founded in 2005 in Bloomington, Ind., and is developing a network of proton therapy centers in cities across the United States. For more information, visit www.procure.com/il.